Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN4OGH)

Drug Name

TAK-960 Drug Info

Synonyms

TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 53357478
TTD Drug ID: DMN4OGH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Polo-like kinase 1 (PLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[3]
Volasertib	DMOFH1M	Acute myeloid leukaemia	2A60	Phase 3	[4]
PCM-075	DMYFRTB	Acute myeloid leukaemia	2A60	Phase 2	[5]
BI 2536	DMJSADP	Acute myeloid leukaemia	2A60	Phase 2	[6]
MK-1496	DME1ZAH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
GSK461364	DM0P729	Non-hodgkin lymphoma	2B33.5	Phase 1	[6]
CYC140	DMC6PKJ	Acute myeloid leukaemia	2A60	Phase 1	[8]
Dihydropyrido pyrazinone compound 3	DM3PEUN	N. A.	N. A.	Patented	[9]
Dihydropyrido pyrazinone compound 2	DMOTG2Y	N. A.	N. A.	Patented	[9]
HMN-214	DMH4ANG	Pancreatic cancer	2C10	Discontinued in Phase 1	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Polo-like kinase 1 (PLK1)	TTIYVQP	PLK1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01179399) Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies. U.S. National Institutes of Health.
2	TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9.
3	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70.
7	J Clin Oncol 29: 2011 (suppl; abstr 3012).
8	Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals.
9	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.